Clinical Trials
Below are current clinical trials.
2036 studies in Mayo Clinic Comprehensive Cancer Center — Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to investigate the effectiveness and safety of UroGen's UGN-102 to treat patients with Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence.
-
Rochester, Minn.
The purpose of this study is to learn more about cancer patients and their health. We are asking participants to complete a survey in order to collect this information. About 220 people will take part in this study.
-
Rochester, Minn.
The objective of this study is to validate internally developed assays for the detection of clinically relevant gene mutations in cfDNA from the peripheral blood of patients with non-small cell lung carcinoma.
-
Rochester, Minn.
The goal of this study is to correlate protein content in vestibular schwannomas and cerebrospinal fluid to patient outcomes, imaging findings, and other relevant clinical endpoints in patients who presented with both this tumor type and hydrocephalus.
-
Rochester, Minn.
The purpose of this study is to:
- Understanding how to better predict and manage patients at high risk for rheumatic irAEs and tailor therapy without diminishing cancer treatment efficacy and,
- Further inform our understanding on the pathogenesis of classic rheumatologic diseases.
- Establish a repository of biological samples from patients with irAE and corresponding rheumatologic
-
Scottsdale/Phoenix, Ariz., Rochester, Minn.
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer). Two cohorts will be enrolled in parallel in this study: the second-line (2L) Cohort will consist of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Cohort will consist of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible patients will be assigned to one of several treatment arms.
-
Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this trial is to determine the safety of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation. Proton therapy is recognized as a standard option for the delivery of radiotherapy for breast cancer.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to assess how using lidocaine jelly in Mohs surgery impacts the overall quantity of lidocaine/epinephrine injectable needed to maintain anesthesia, and patients’ pain/anxiety associated with anesthesia injections.
-
Rochester, Minn.
This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.
We would like to see if use of topical ketoconazole will improve rashes in patients with EGFR inhibitor-induced rash.
-
Rochester, Minn.
The purose of this study is to examine the characteristics and post-surgical outcomes of pediatric patients diagnosed with lipoblastoma.